Mitotane treatment in patients with metastatic testicular Leydig cell tutor associated with severe androgen excess

Research output: Contribution to journalArticlepeer-review

Standard

Mitotane treatment in patients with metastatic testicular Leydig cell tutor associated with severe androgen excess. / Chortis, Vasileios; Johal, Nicholas J.; Bancos, Irina; Evans, Matthew; Skordilis, Kassiani; Guest, Peter; Cullen, Michael H.; Porfiri, Emilio; Arlt, Wiebke.

In: European Journal of Endocrinology, 12.01.2018.

Research output: Contribution to journalArticlepeer-review

Harvard

APA

Vancouver

Author

Chortis, Vasileios ; Johal, Nicholas J. ; Bancos, Irina ; Evans, Matthew ; Skordilis, Kassiani ; Guest, Peter ; Cullen, Michael H. ; Porfiri, Emilio ; Arlt, Wiebke. / Mitotane treatment in patients with metastatic testicular Leydig cell tutor associated with severe androgen excess. In: European Journal of Endocrinology. 2018.

Bibtex

@article{3e8375d99979434f8a9dd7422dc0b587,
title = "Mitotane treatment in patients with metastatic testicular Leydig cell tutor associated with severe androgen excess",
abstract = "Mitotane (o,p'DDD) is established in the adjuvant and advanced stage treatment of adrenocortical carcinoma and counteracts both tumour growth and tumour-related steroid production. Both the adrenal glands and the gonads are steroidogenically active organs and share a common embryogenic origin. Here we describe the effects of mitotane in two patients with metastatic Leydig cell tumour (LCT) of the testes and associated severe androgen excess (serum testosterone 93 and 88 nmol/l, respectively; male reference range 7-27 nmol/L). Both men suffered from severe restlessness, insomnia and irritability, which they described as intolerable and disrupting normal life activities. Urinary steroid profiling by gas chromatography-mass spectrometry (GC-MS) confirmed excess androgen production and revealed concurrent overproduction of glucocorticoids and glucocorticoid precursors, which under physiological conditions are produced only by the adrenal glands but not by the gonads. In a palliative approach, they were commenced on mitotane, which achieved swift control of the hormone excess and the debilitating clinical symptoms, restoring normal quality of life. GC-MS demonstrated normalization of steroid production and decreased 5-reductase activity, resulting in decreased androgen activation, and imaging demonstrated disease stabilization for 4-10 months. In conclusion, mitotane can be highly effective in controlling steroid excess in metastatic LCTs, with anti-tumour activity in some cases.",
keywords = "Journal Article, mitotane , metastatic Leydig cell tumour , androgen excess , SOAT1 , mass spectrometry",
author = "Vasileios Chortis and Johal, {Nicholas J.} and Irina Bancos and Matthew Evans and Kassiani Skordilis and Peter Guest and Cullen, {Michael H.} and Emilio Porfiri and Wiebke Arlt",
year = "2018",
month = jan,
day = "12",
doi = "10.1530/EJE-17-0542",
language = "English",
journal = "European Journal of Endocrinology",
issn = "0804-4643",
publisher = "BioScientifica",

}

RIS

TY - JOUR

T1 - Mitotane treatment in patients with metastatic testicular Leydig cell tutor associated with severe androgen excess

AU - Chortis, Vasileios

AU - Johal, Nicholas J.

AU - Bancos, Irina

AU - Evans, Matthew

AU - Skordilis, Kassiani

AU - Guest, Peter

AU - Cullen, Michael H.

AU - Porfiri, Emilio

AU - Arlt, Wiebke

PY - 2018/1/12

Y1 - 2018/1/12

N2 - Mitotane (o,p'DDD) is established in the adjuvant and advanced stage treatment of adrenocortical carcinoma and counteracts both tumour growth and tumour-related steroid production. Both the adrenal glands and the gonads are steroidogenically active organs and share a common embryogenic origin. Here we describe the effects of mitotane in two patients with metastatic Leydig cell tumour (LCT) of the testes and associated severe androgen excess (serum testosterone 93 and 88 nmol/l, respectively; male reference range 7-27 nmol/L). Both men suffered from severe restlessness, insomnia and irritability, which they described as intolerable and disrupting normal life activities. Urinary steroid profiling by gas chromatography-mass spectrometry (GC-MS) confirmed excess androgen production and revealed concurrent overproduction of glucocorticoids and glucocorticoid precursors, which under physiological conditions are produced only by the adrenal glands but not by the gonads. In a palliative approach, they were commenced on mitotane, which achieved swift control of the hormone excess and the debilitating clinical symptoms, restoring normal quality of life. GC-MS demonstrated normalization of steroid production and decreased 5-reductase activity, resulting in decreased androgen activation, and imaging demonstrated disease stabilization for 4-10 months. In conclusion, mitotane can be highly effective in controlling steroid excess in metastatic LCTs, with anti-tumour activity in some cases.

AB - Mitotane (o,p'DDD) is established in the adjuvant and advanced stage treatment of adrenocortical carcinoma and counteracts both tumour growth and tumour-related steroid production. Both the adrenal glands and the gonads are steroidogenically active organs and share a common embryogenic origin. Here we describe the effects of mitotane in two patients with metastatic Leydig cell tumour (LCT) of the testes and associated severe androgen excess (serum testosterone 93 and 88 nmol/l, respectively; male reference range 7-27 nmol/L). Both men suffered from severe restlessness, insomnia and irritability, which they described as intolerable and disrupting normal life activities. Urinary steroid profiling by gas chromatography-mass spectrometry (GC-MS) confirmed excess androgen production and revealed concurrent overproduction of glucocorticoids and glucocorticoid precursors, which under physiological conditions are produced only by the adrenal glands but not by the gonads. In a palliative approach, they were commenced on mitotane, which achieved swift control of the hormone excess and the debilitating clinical symptoms, restoring normal quality of life. GC-MS demonstrated normalization of steroid production and decreased 5-reductase activity, resulting in decreased androgen activation, and imaging demonstrated disease stabilization for 4-10 months. In conclusion, mitotane can be highly effective in controlling steroid excess in metastatic LCTs, with anti-tumour activity in some cases.

KW - Journal Article

KW - mitotane

KW - metastatic Leydig cell tumour

KW - androgen excess

KW - SOAT1

KW - mass spectrometry

U2 - 10.1530/EJE-17-0542

DO - 10.1530/EJE-17-0542

M3 - Article

C2 - 29330226

JO - European Journal of Endocrinology

JF - European Journal of Endocrinology

SN - 0804-4643

ER -